Fig. 3.

iTPNCs suppress tumor growth. (A) Schematic and timeline for intratumoral injections. S.c. flank B16F10 murine melanoma tumors were injected intratumorally with ODN 1826 naked or formulated in iTPNCs (0.2 nmol ODN per injection) and tumors were measured over time. Tumors were injected on days indicated by pink arrowheads. (B) Bars show average final tumor volume at experimental endpoint on day 20 for each treatment group. (*P = 0.0155, unpaired t test; n = 8 tumors per group, data are representative of three independent experiments). (C) Images of H&E-stained sections of representative tumors from B. (Scale bars, 2 mm.)